An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

By M. R. D. Christenson. 2012

2,643 citations recorded by the source corpus.

Subfields: Public Health, Environmental and Occupational Health, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/b9d365014488258da612242dd896cfecb1aba573

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Public Health, Environmental and Occupational Health

1. P. Noble
2. B. Stripp
3. B. Hogan
4. Emily Bowie
5. C. E. Barkauskas
6. S. Randell
7. Michael J. Cronce
8. D. Keene

In Pulmonary and Respiratory Medicine

1. P. Noble
2. G. Raghu
3. David M. Mannino
4. B. Stripp
5. B. Hogan
6. Emily Bowie
7. C. E. Barkauskas
8. S. Randell

Citations in the corpus

• Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. (2017, neutral): “53 These patients, who might have been termed as “inconsistent with UIP” under the 2011 guidelines, 1 should be considered as indeterminate for UIP .”
• An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. (2012, background): “In the appropriate clinical setting it has been recommended that the recognition of precise radiologic and/or surgical lung biopsy characteristics is sufficient to make a specific diagnosis of IPF (4).”
• A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. (2015, positive): “In the most recent American Thoracic Society consensus document, transplantation and supplemental oxygen were the only treatments strongly recommended for patients with IPF, and a transplant discussion was recommended at the time of diagnosis.(25) The evidence reviewed here focuses on IPF as the mos”
• Ageing and the epidemiology of multimorbidity (2014, background): “As noted earlier, the prevalence estimates for ILDs vary greatly [20, 52–56] and are much lower than that of COPD.”
• Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. (2012, background): “At present, no effective therapeutic options exist to slow progression of IPF (11).”
• Type 2 alveolar cells are stem cells in adult lung. (2013, positive): “their obliteration in idiopathic pulmonary fibrosis (IPF) (7).”